수모세포종과 대뇌 원시 신경외배엽 종양의 면역조직화학적 연구

이정일,왕규창,지제근,조병규 대한신경외과학회 1995 Journal of Korean neurosurgical society Vol.24 No.8

Although it is becoming widely accepted that medulloblastoma and cerebral primitive neuroectodermal tumor(PNET) are identical tumors occuring at different locations, there are some controversies in their origin and pathological classification. As a method of investigating whether the tumors are identical in pathological aspects, immunohistochemical characteristics of medulloblastomas and cerebral PNETs were compared in this study. Also the prognostic significance of the immunohistochemical findings in modulloblastoma patients was analyzed. Clinical features of twenty-seven patients with modulloblastoma and eleven patients with cerebral PNET were reviewed, excluding tumors with significant cellular differentiation such as ependymoblastoma, pineoblastoma and neuroblastoma. The presence of glial fibrillary acidic protein(GFAP), neurofilament(NF), S-100 protein, vimentin synaptophysin, and epithelial membrane antigen (EMA) was examined with immunohistochemical method and the differences of the results between the two tumors were statistically analyzed. The positive rates of NF and synaptophysin were significantly higher in medulloblastomas(p = 0.006 and 0.003, respectively) and so was the positive rate of vimentin in cerebral PNETs(p=0.004). S-100 protein showed a higher positive rate in cerebral PNETs although it was not statistically significant Univariate and multivariate analyses did not show any significant correlation between the duration of survival and the presence of cellular antigens.

고립성 폐결절의 조직학적 진단에 있어서 경기관지폐생검의 진단적 가치

김치훈,김정주,왕준호,연규민,김형수,리원연,용석중,신계철 건국대학교 의과학연구소 2002 건국의과학학술지 Vol.12 No.-

Transbronchial lung biopsy(TBLB) is a relatively simple and convenient diagnostic tool in solitary pulmonary nodule(SPN) on chest radiograph, which is cannot be diagnosed through routine tests. To investigate the diagnostic value and diagnostic rate of TBLB according to the variable factor, we analyzed 69 patients with radiologically SPN lesion on chest radiograph which was confirmed histologically. A histologic diagnosis of TBLB was made in 47 of 69 patients(68.1%), in which 26 of 37(70.3%) with malignancy and 21 of 32(65.6%) with benign lesion. There were no significant differences in diagnostic yield according to age, sex and location of the lesion. The diagnostic rate tended to increase with the more than 5 pieces to acquired by TBLB. When the size of SPN was less than 3 ㎝, it cannot be diagnosed. In conclusion, TBLB is a diagnostic procedure with good yield and safety, but percutaneous needle aspiration, transbronchial needle aspiration, and bronchial washing fluid cytology may be a complementary procedure to overcome the limitation of TBLB and get higher diagnostic yield for SPN.

Transient Knock Down of Grp78 Reveals Roles in Serum Ferritin Mediated Pro-inflammatory Cytokine Secretion in Rat Primary Activated Hepatic Stellate Cells

Wang, Chi-Mei,Li, Shan-Jen,Wu, Chi-Hao,Hu, Chien-Ming,Cheng, Hui-Wen,Chang, Jung-Su Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.2

Chronic liver diseases, including cancer, are characterized by inflammation and elevated serum ferritin (SF). However, the causal-relationship remains unclear. This study used primary rat hepatic stellate cells (HSC) as a model to investigate effects of physiological SF concentrations (10, 100 and 1000 pM) because HSCs play a central role in the development and progression of liver fibrosis. Physiological concentrations of SF, either horse SF or human serum, induced pro-inflammatory cytokine $IL1{\beta}$, IL6 and $TNF{\alpha}$ secretion in rat activated HSCs (all p<0.05). By contrast, treatment did not alter activation marker ${\alpha}SMA$ expression. The presence of SF markedly enhanced expression of Grp78 mRNA (p<0.01). Furthermore, transient knock down of Grp78 by endotoxin EGF-SubA abolished SF-induced $IL1{\beta}$ and $TNF{\alpha}$ secretion in activated HSCs (all p<0.05). In conclusion, our results showed that at physiological concentrations SF functions as a pro-inflammatory mediator in primary rat HSCs. We also provide a molecular basis for the action of SF and identified Grp78-associated ER stress pathways as a novel potential therapeutic target for resolution of fibrosis and possible prevention of liver cancer.

Intense X-ray induced formation of silver nanoparticles stabilized by biocompatible polymers

Wang, Chang-Hai,Liu, Chi-Jen,Wang, Cheng-Liang,Chien, Chia-Chi,Hwu, Y.,Liu, Ru-Shi,Yang, Chung-Shi,Je, Jung-Ho,Lin, Hong-Ming,Margaritondo, G. Springer-Verlag 2009 Applied physics. A, Materials science & processing Vol.97 No.2

Fibromyalgia diagnosis: a review of the past, present and future

Wang, Sheng-Min,Han, Changsu,Lee, Soo-Jung,Patkar, Ashwin A,Masand, Prakash S,Pae, Chi-Un Informa UK, Ltd 2015 Expert review of neurotherapeutics Vol.15 No.6

<P>Diagnosis of fibromyalgia (FM) remains controversial even though diverse diagnostic criteria have been developed. This review looks at the history, evolution of diagnostic criteria, endless controversy, recent trends and future perspectives regarding FM diagnosis. Some have criticized that diagnosis of FM could lead to medicalization, whereas others have raised concerns of under-diagnosing FM. With the evolution of diagnosis criteria from American College of Rheumatology 1990 to modified American College of Rheumatology 2010, diagnosis of FM has become simpler. The recent trend of applying patient-reported questionnaires has also increased a simpler FM diagnosis. Reliable biomarkers will not be available for the foreseeable future, so diverse assessment tools will have to be used more pro-actively. After initial diagnosis, multiple and comprehensive assessment measures are needed during the course of treatment in order to better understand type and severity of FM symptoms. These, in turn, could help classify FM based on symptom domain, symptom severity, and comorbidity which would enable more personalized treatment.</P>

A review of current evidence for vilazodone in major depressive disorder

Wang, Sheng-Min,Han, Changsu,Lee, Soo-Jung,Patkar, Ashwin A.,Masand, Prakash S.,Pae, Chi-Un Informa Healthcare 2013 International journal of psychiatry in clinical pr Vol.17 No.3

<P><I>Objectives.</I> This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its differential action mechanism and extended clinical utility. <I>Methods.</I> A data search was conducted in June 2012 using the PubMed/ MEDLINE/relevant clinical trial databases with the key terms “vilazodone” or “Viibryd.” <I>Results.</I> The efficacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side effects, the absence of known cardiac toxicity, and minimal effect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side effects. No direct comparative studies with other antidepressants are currently available to confirm the aforementioned potential clinical utility. <I>Conclusion.</I> Vilazodone is a newer antidepressant possessing different action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of efficacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.</P>

Five potential therapeutic agents as antidepressants: a brief review and future directions

Wang, Sheng-Min,Han, Changsu,Lee, Soo-Jung,Patkar, Ashwin A,Masand, Prakash S,Pae, Chi-Un 'Informa Healthcare (Expert Reviews, LTD)' 2015 Expert review of neurotherapeutics Vol.15 No.9

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Wang, Sheng-Min,Han, Changsu,Lee, Soo-Jung,Jun, Tae-Youn,Patkar, Ashwin A,Masand, Prakash S,Pae, Chi-Un Chonnam National University Medical School 2016 CMJ Vol.52 No.3

<P>Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.</P>

Emerging 2D material-based nanocarrier for cancer therapy beyond graphene

Wang, Yingwei,Qiu, Meng,Won, Miae,Jung, Eugeine,Fan, Taojian,Xie, Ni,Chi, Sung-Gil,Zhang, Han,Kim, Jong Seung Elsevier 2019 Coordination Chemistry Reviews Vol.400 No.-

<P><B>Abstract</B></P> <P>2D materials (e.g., graphene, graphene analogues), with unique physical and chemical properties, shows intriguing potential for the realization of versatile biomedical applications. Tremendous attention has been attracted on 2D material based nanocarriers, which play a crucial role in therapeutic drug, gene, and biomedical agent delivery for cancer theranostics. This review provides an up-to-date review on the development of nanocarriers based on 2D materials beyond graphene, including basic and emerging synthesis methods, the catalog of 2D material-based nanocarriers, biosafety, surface functional engineering, the realization of stimuli-responsive controllable release and biomedical applications. Among the properties and performance to be summarized, there is particular focus on nanocarriers loading capability, biosafety, and therapy efficiency and so on. Finally, by addressing major issues and challenges, some prospects for future directions in this area are provided.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Highlight the emerging 2D material based nanocarriers for biomedical applications. </LI> <LI> Summarized surface engineering strategy used in nanocarriers. </LI> <LI> Overview the biomedical application of 2D material nanocarriers. </LI> <LI> Give a guide to design stimuli-responsive controllable drug release strategy. </LI> <LI> Proposed insightful prospects for the future development of 2D material based nanocarriers application. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review

Wang, Sheng-Min,Han, Changsu,Bahk, Won-Myoung,Lee, Soo-Jung,Patkar, Ashwin A.,Masand, Prakash S.,Pae, Chi-Un Chonnam National University Medical School 2018 CMJ Vol.54 No.2

<P>Randomized trials have shown that selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have better safety profiles than classical tricyclic antidepressants (TCAs). However, an increasing number of studies, including meta-analyses, naturalistic studies, and longer-term studies suggested that SSRIs and SNRIs are no less safe than TCAs. We focused on comparing the common side effects of TCAs with those of newer generation antidepressants including SSRIs, SNRIs, mirtazapine, and bupropion. The main purpose was to investigate safety profile differences among drug classes rather than the individual antidepressants, so studies containing comparison data on drug groups were prioritized. In terms of safety after overdose, the common belief on newer generation antidepressants having fewer side effects than TCAs appears to be true. TCAs were also associated with higher drop-out rates, lower tolerability, and higher cardiac side-effects. However, evidence regarding side effects including dry mouth, gastrointestinal side effects, hepatotoxicity, seizure, and weight has been inconsistent, some studies demonstrated the superiority of SSRIs and SNRIs over TCAs, while others found the opposite. Some other side effects such as sexual dysfunction, bleeding, and hyponatremia were more prominent with either SSRIs or SNRIs.</P>